News

All mice with cystic fibrosis that received iclaprim for a pneumonia infection survived, according to a study. Motif Bio reported the finding, which involved the Staphylococcus aureus bacteria, and the results of another preclinical-trial study at the IDWeek 2017 conference in San Diego, Oct. 4-8. Iclaprim is designed to kill bacteria that develop resistance…

A cystic fibrosis expert will be among more than 80 speakers at this month’s Rare Disease & Orphan Products Breakthrough Summit in Washington. The nonprofit National Organization for Rare Disorders (NORD) will be hosting the sixth annual event Oct. 16-17 at the Marriott Wardman Park Hotel. It is expected to attract…

EBX-001, which consists of two bacteria-fighting compounds, eliminates persistent drug-resistant Pseudomonas aeruginosa in cystic fibrosis patients better than the antibiotic component of the therapy alone, a study reports. The treatment candidate’s developer, EnBiotix, published the results in Antimicrobial Agents & Chemotherapy, a journal of the American Society for Microbiology. The article was…